Getting molnupiravir to patients in a timely way is likely to be problematic

I look forward to seeing more details about the effects of molnupiravir on covid-19, preferably in a peer reviewed publication.1

I have commented on this elsewhere.2

I was involved in trying to get people with flu-like symptoms antiviral chemoprophylaxis in the early days of the 2010 flu pandemic. Because ministers had said that everybody with such symptoms must be given chemoprophylaxis, we were not permitted to prioritise those at greatest …